Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs -- Ignore unavailable to you. Want to Upgrade?

To: Lance Bredvold who wrote (370)	12/24/2001 2:16:15 PM
From: mact	Read Replies (1) \| Respond to of 384

all i can say is that the charts look good to make higher highs.

To: Lance Bredvold who wrote (370)	12/27/2001 2:33:22 PM
From: David Lawrence	Read Replies (1) \| Respond to of 384

>>My impression always was that McKnight was a well respected and loved chairman with charisma and that the president, Puskar, who also was a founder but had been on the sales side rather than administration, was not regarded with much respect by either the scientific or business community. Thus it is my suspicion that Mylan carried an unjustified amount of good will and enthusiasm for magical growth through the early 90's and there has been a more realistic or at least lower expectation of growth in years since McKnight died.<< Your impression regarding McKnight's standing is right on the money. He was also highly respected on Capital Hill, and was an excellent representative of the generic Rx industry. That was the justification for the high degree of goodwill directed toward the company. Puskar, on the other hand, was generally viewed in the opposite light, and thus has not and probably never will inspire the goodwill that his predecessor received. ICN Pharmaceuticals is a somewhat similar story, with a thug named Milan Panic (former Yugoslovian PM) in the leadership role. He recently lost a proxy fight over three seats on the BOD, and will now be forced to restructure the company in order to achieve maximum shareholder value. It's taken years to accomplish that despite his efforts to the contrary. Don't discount the effect the standing of the CEO or CBOD can have on the value of a stock. Many investors invest on the basis of their perception of management, and its presence or absence can cause the P/E to swing several points in either direction.